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Pharmacokinetics of
Everolimus Eluted From
the Absorb Bioresorbable
Vascular Scaffold
An ABSORB III SubstudyThe Absorb bioresorbable vascular scaffold (BVS)
(Abbott Vascular, Santa Clara, California) is designed
to reduce chronic adverse cardiovascular events that
may occur from the permanent presence of a metallic
stent and/or durable polymer. The systemic pharma-
cokinetic (PK) proﬁle of BVS has not been described.
ABSORB III PK is a prospective, open-label, non-
randomized substudy of the ABSORB III randomized
trial (1), in which either 1 (n ¼ 8) or 2 (n ¼ 4) BVS were
implanted in de novo coronary artery stenoses.
Inclusion/exclusion criteria were the same as for
ABSORB III (1), namely noncomplex lesions in pa-
tients with stable ischemic heart disease or stabilized
acute coronary syndromes. All patients provided
written informed consent for this substudy and were
enrolled following successful BVS deployment at
2 U.S. sites between June 2, 2014, and September
17, 2014.
Detailed methods for the PK analysis are described
elsewhere (1). Brieﬂy, subjects had blood drawn at 16
time points between pre-procedure and 30 days (prior
to implantation of the ﬁrst BVS and at 10 min, 30 min,
and 1, 2, 4, 6, 12, 24, 48, 72, 96, 120 [day 5], 168 [day 7],
336 [day 14], and 720 [day 30] h after last BVS
deployment). Everolimus blood concentrations were
measured, and noncompartmental analysis was per-
formed to determine PK parameters (Cmax, tmax, t1/2,
AUC24h, AUClast, and AUC0–N). To explore dose pro-
portionality of everolimus, a regression analysis on
dose-normalized (to 1 mg) PK parameters for ever-
olimus was performed. Blood concentration-time
proﬁles and PK parameters of everolimus were
compared with prior PK results obtained from the
Xience V cobalt chromium everolimus-eluting stent
(CoCr-EES) (Abbott Vascular) in the SPIRIT II and III
(Clinical Evaluation of the XIENCE V EverolimusEluting Coronary Stent System in the Treatment of
Subjects with de Novo Native Coronary Artery
Lesions) trial substudies (2,3).
Twelve patients were enrolled, all of whom
remained in the PK substudy through 30 days. The
mean age was 60.1 years, and 91.7% of subjects were
male. Risk factors included current tobacco use
(25.0%), diabetes (33.3%), hypertension (100%), dys-
lipidemia (100%), and prior MI (18.2%). Stable or
unstable angina was present in 75% and 25% of sub-
jects, respectively. The target lesion was the left
circumﬂex artery in 50% of patients, the left anterior
descending artery in 42%, and the right coronary ar-
tery in 8%. One-third of lesions were moderately
or severely calciﬁed. Mean lesion length was 12.2 
4.4 mm, and mean pre-procedure reference vessel
diameter was 2.73  0.41 mm. Scaffold diameters
ranged from 2.5 to 3.5 mm, and scaffold lengths
ranged from 8 to 28 mm. The average total length
of scaffold implanted at the lesion site was 24.5 
8.6 mm. The total dose of loaded everolimus ranged
from 181 to 443 mg.
Individual tmax ranged from 0.17 to 2.37 h across all
dose levels. Everolimus blood concentrations could
be quantiﬁed for up to 168 h after implantation of the
last BVS (Figure 1A). Individual Cmax values increased
proportionally with dose, ranging from 1.085 to 4.460
ng/ml. Similarly, individual AUC24h (ranging from
12.09 to 44.22 ng$h/ml), AUClast (ranging from 25.37 to
104.60 ng$h/ml) and AUC0–N (ranging from 33.15 to
120.80 ng$h/ml) increased proportionally with dose.
Terminal half-life ranged from 45.9 to 115.0 h, with
no obvious trend with dose. Interindividual variability
(% coefﬁcient of variation) in everolimus exposure
after BVS deployment ranged between 23.3% and
35.6% for dose-normalized Cmax, AUC24h, AUClast, and
AUC0–N.
Although short-lived, individual Cmax values
(1.085 to 4.460 ng/ml) were slightly higher than the
minimum systemic, chronically maintained thera-
peutic level of $3.0 ng/ml required for effective
prevention of organ rejection (4). However, ever-
olimus blood concentrations declined rapidly after
reaching Cmax and were <3.0 ng/ml in all subjects by
4 h after the last scaffold deployment. In addition,
Cmax levels obtained after Absorb BVS were well
below mean steady-state Cmax (61 ng/ml) observed in
FIGURE 1 BVS Compared With CoCr-EES in the SPIRIT II and III Trials
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Mean  SD whole blood everolimus blood concentration-time curves for bioresorbable
vascular scaffolds (BVS) with different everolimus loads (A), and for BVS compared with
cobalt chromium everolimus-eluting stents (CoCr-EES) from the earlier SPIRIT II and III
trials (B). B displays the comparative concentration-time data after a 181 mg dose from a
total of 13 subjects from the SPIRIT II (n ¼ 4), SPIRIT III (n ¼ 6), and ABSORB III PK (n ¼ 3)
studies. Each subject received 1 scaffold/stent (Absorb: size 2.5  18 mm [n ¼ 1] or 3.0 
18 mm [n ¼ 2]; SPIRIT II: size 3.5  28 mm [n ¼ 3] or 4.0  28 mm [n ¼ 1]; SPIRIT III: size
3.5  28 mm [n ¼ 3] or 4.0  28 mm [n ¼ 3]). The dose ranges studied in the SPIRIT trials
ranged from 53 mg to 588 mg (SPIRIT II) and 53 mg to 181 mg (SPIRIT III), versus 181 mg
to 443 mg in the ABSORB III PK study; 181 mg was the only common dose device across
these studies.
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2468patients with solid tumors treated with 10 mg/day of
everolimus (5).
These results are consistent with 2 prior PK
studies of everolimus elution from the metallic
XIENCE V stent (2,3), which has the same drug dose
density as BVS (100 mg/cm2) (Figure 1B). Examining
the concentration-time PK results from the BVS
scaffold and the CoCr-EES stent with a common load
of 181 ug of everolimus, both devices demonstrated
a rapid increase in systemic everolimus levels
after stent/scaffold deployment, reaching maximal
concentrations within 2.5 h, followed by a biexpo-
nential decline, with an initial rapid phase followedby a slower terminal phase; levels remained above
the limit of detection (0.1 ng/ml) for up to 168 h
after stent/scaffold deployment. Similar to CoCr-
EES, an increase in total everolimus dose by BVS
resulted in a proportional increase in Cmax and AUC
(Figure 1A). Although the early peak everolimus
concentrations with BVS appear slightly higher than
with CoCr-EES, inferences should not be drawn
from small differences as the studies with the 2 de-
vices were done at different times in different
patients.
In conclusion, the systemic PK characteristics of
everolimus after BVS deployment are predictable
with dose-proportional behavior. Local coronary
arterial delivery results in limited systemic expo-
sure, suggesting a low risk of systemic toxicity.
The PK proﬁle of systemic everolimus exposure
from BVS is similar to that from the metallic
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Abolishes High-Density
Lipoprotein–Related
Cardioprotective Effects
in the Setting of
Myocardial InfarctionEpidemiological studies have consistently reported
that high-density lipoprotein (HDL) cholesterol levels
are inversely associated with the risk of cardiovascular
disease (CVD) (1). In fact, plasma-derived and syn-
thetic HDL, and/or its derivatives, have been shown
to exert various cardiovascular protective effects
ranging from reverse cholesterol transport, athero-
sclerotic plaque stabilization, improvement of endo-
thelial dysfunction (2), and most lately, limiting
infarct size (3). However, in this latter regard, it
remains unknown whether the presence of cardio-
vascular risk factors attenuates HDL-related cardio-
vascular protection. We investigated whether the
presence of high low-density lipoprotein cholesterol
levels, a prominent risk factor for CVD, affects ability
of HDL to exert direct cardioprotective effects. We
conducted this study in a pre-clinical animal model of
myocardial infarction (MI) as a biological readout of
the differential effects of HDL when formed in a high-
cholesterol pathological environment.
Young healthy pigs were distributed to receive
during 10 days either a regular normocholesterolemic
chow (NC) or a high-cholesterol diet (HyC) (non-HDL
cholesterol 38.2  3.5 mg/dl vs. 218.6  27.6 mg/dl,
respectively; p < 0.0001). On day 10, HDLs were iso-
lated from NC- and HyC-fed animals by sequential
ultracentrifugation (NCHDL and HyCHDL, respectively)
and were quantiﬁed, sterilized, lyophilized, and kept
at 80C until use. Another set of young healthy pigs
were randomized to receive 2 intravenous infusions
3 days apart of NCHDL (15 mg/kg; n ¼ 6), HyCHDL
(15 mg/kg; n ¼ 6), or vehicle (phosphate-buffered sa-
line; n ¼ 6). One day after the second infusion, ani-
mals were subjected to 60-min closed-chest coronary
balloon occlusion followed by reperfusion (experi-
mental MI). Echocardiography revealed that 60 min
of ischemia signiﬁcantly and similarly worsened left
ventricle ejection fraction in all animals showing
the homogeneity of the employed methodologicalapproach (vehicle: 19.6  4.8%; NCHDL: 20.6  3.2%;
HyCHDL: 17.3  2.1%; p < 0.05 vs. prior MI induction).
Three days post-MI, all animals underwent cardiac
magnetic resonance, and the following sequences
were acquired: 1) “cine” (balanced steady-state free
precession) imaging sequence to assess wall motion
and cardiac function; 2) T2-short tau inversion re-
covery sequence to assess myocardial edema; 3) T2* to
evaluate intramyocardial hemorrhage; 4) early gado-
linium enhancement to evaluate the degree of no-
reﬂow; and 5) late gadolinium enhancement to assess
the extent of myocardial necrosis. Data were normally
distributed (Shapiro-Wilk Test) and analysis of vari-
ance, Fisher least signiﬁcant difference, and post-hoc
Student-Newman-Keuls analyses were performed.
A value of p < 0.05 was considered signiﬁcant.
Infusion of NCHDL before MI resulted in a signiﬁ-
cantly smaller infarct size, in terms of both absolute
infarct mass and percentage of the left ventricle,
compared with vehicle-infused animals (Table 1). This
protective effect did not occur in animals infused
with HyCHDL. T2-weighted sequences revealed no
differences in the extent of area-at-risk among
the 3 groups. Consequently, the extent of salvage
myocardium was signiﬁcantly larger in the NCHDL-
administered group compared with the HyCHDL and
vehicle control groups. The extent of no-reﬂow was
also signiﬁcantly attenuated in the NCHDL-infused
group compared with HyCHDL and vehicle animals
and directly correlated with the extent of necrosis
(p < 0.05; R ¼ 0.63). No differences were observed
between HyCHDL-recipient animals and vehicle con-
trols with regard to infarct size, myocardial salvage,
and no-reﬂow. The extent of hemorrhage was compa-
rable among the 3 groups. Although left ventricular
ejection fraction assessed 3 days post-MI did not differ
between the groups (Table 1), left ventricular volumes
signiﬁcantly improved in NCHDL-recipient animals
compared with HyCHDL- and vehicle-infused animals.
We describe, for the ﬁrst time, that hypercholes-
terolemia, a common risk factor for CVD, impairs the
cardioprotective properties commonly associated
with HDL. We provide evidence that HDL particles
formed in a high low-density lipoprotein cholesterol
niche lose their capability to attenuate myocardial
damage in the setting of MI. As such, the degree of
cardiac injury and cardiac impairment observed in
HyCHDL-infused animals is comparable to that
observed in vehicle-infused animals. These observa-
tions suggest that the presence of comorbidities may
alter HDL’s beneﬁcial properties. Particularly note-
worthy, in contrast to primary prevention, the asso-
ciation between HDL cholesterol and cardiovascular
events is altered in patients with established CVD
